Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum

[Introduction] Neuroimaging heterogeneity in dementia has been examined using single modalities. We evaluated the associations of magnetic resonance imaging (MRI) atrophy and flortaucipir positron emission tomography (PET) clusters across the Alzheimer's disease (AD) spectrum.

Detalhes bibliográficos
Autores: Toledo, Jon B., Liu, Hangfan, Grothe, Michel J., Rashid, Tanweer, Launer, Lenore, Shaw, Leslie M., Snoussi, Haykel, Heckbert, Susan, Weiner, Michael, Trojanwoski, John Q., Seshadri, Sudha, Habes, Mohamad
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/305454
Acesso em linha:http://hdl.handle.net/10261/305454
https://api.elsevier.com/content/abstract/scopus_id/85138700262
Access Level:acceso abierto
Palavra-chave:Alzheimer's disease
Amyloid beta
Heterogeneity
Mangetic resonance imaging
Positron emission tomography
Prognosis
Tau
id ES_1735571736ae965cd2a8cb1e8a6b8ba2
oai_identifier_str oai:digital.csic.es:10261/305454
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
title Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
spellingShingle Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
Toledo, Jon B.
Alzheimer's disease
Amyloid beta
Heterogeneity
Mangetic resonance imaging
Positron emission tomography
Prognosis
Tau
title_short Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
title_full Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
title_fullStr Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
title_full_unstemmed Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
title_sort Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
dc.creator.none.fl_str_mv Toledo, Jon B.
Liu, Hangfan
Grothe, Michel J.
Rashid, Tanweer
Launer, Lenore
Shaw, Leslie M.
Snoussi, Haykel
Heckbert, Susan
Weiner, Michael
Trojanwoski, John Q.
Seshadri, Sudha
Habes, Mohamad
author Toledo, Jon B.
author_facet Toledo, Jon B.
Liu, Hangfan
Grothe, Michel J.
Rashid, Tanweer
Launer, Lenore
Shaw, Leslie M.
Snoussi, Haykel
Heckbert, Susan
Weiner, Michael
Trojanwoski, John Q.
Seshadri, Sudha
Habes, Mohamad
author_role author
author2 Liu, Hangfan
Grothe, Michel J.
Rashid, Tanweer
Launer, Lenore
Shaw, Leslie M.
Snoussi, Haykel
Heckbert, Susan
Weiner, Michael
Trojanwoski, John Q.
Seshadri, Sudha
Habes, Mohamad
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Michael J. Fox Foundation for Parkinson's Research
Instituto de Salud Carlos III
European Commission
National Institutes of Health (US)
San Antonio Medical Foundation
National Institute on Aging (US)
National Institute of Biomedical Imaging and Bioengineering (US)
AbbVie Pharmaceuticals
Alzheimer's Association
Alzheimer Drug Discovery Foundation
Araclon Biotech
BioClinica
Biogen
Bristol-Myers Squibb
CereSpir
Cogstate
Eisai
Elan Pharmaceuticals
Eli Lilly and Company
EuroImmun Diagnostics
Hoffmann-La Roche
Genentech
Fujirebio Europe
GE Healthcare
IXICO
Janssen Alzheimer Immunotherapy
Johnson and Johnson Pharmaceutical Research and Development
Lumosity
Lundbeck
Merck & Co
Meso Scale Diagnostics
NeuroRx
Neurotrack
Novartis
Pfizer
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Toledo, Jon B. [0000-0003-4366-9268]
Habes, Mohamad [0000-0001-9447-5805]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Alzheimer's disease
Amyloid beta
Heterogeneity
Mangetic resonance imaging
Positron emission tomography
Prognosis
Tau
topic Alzheimer's disease
Amyloid beta
Heterogeneity
Mangetic resonance imaging
Positron emission tomography
Prognosis
Tau
description [Introduction] Neuroimaging heterogeneity in dementia has been examined using single modalities. We evaluated the associations of magnetic resonance imaging (MRI) atrophy and flortaucipir positron emission tomography (PET) clusters across the Alzheimer's disease (AD) spectrum.
publishDate 2022
dc.date.none.fl_str_mv 2022
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/305454
https://api.elsevier.com/content/abstract/scopus_id/85138700262
url http://hdl.handle.net/10261/305454
https://api.elsevier.com/content/abstract/scopus_id/85138700262
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1002/trc2.12305
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Alzheimer’s Association
John Wiley & Sons
publisher.none.fl_str_mv Alzheimer’s Association
John Wiley & Sons
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403906503606272
spelling Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuumToledo, Jon B.Liu, HangfanGrothe, Michel J.Rashid, TanweerLauner, LenoreShaw, Leslie M.Snoussi, HaykelHeckbert, SusanWeiner, MichaelTrojanwoski, John Q.Seshadri, SudhaHabes, MohamadAlzheimer's diseaseAmyloid betaHeterogeneityMangetic resonance imagingPositron emission tomographyPrognosisTau[Introduction] Neuroimaging heterogeneity in dementia has been examined using single modalities. We evaluated the associations of magnetic resonance imaging (MRI) atrophy and flortaucipir positron emission tomography (PET) clusters across the Alzheimer's disease (AD) spectrum.[Methods] We included 496 Alzheimer's Disease Neuroimaging Initiative participants with brain MRI, flortaucipir PET scan, and amyloid beta biomarker measures obtained. We applied a novel robust collaborative clustering (RCC) approach on the MRI and flortaucipir PET scans. We derived indices for AD-like (SPARE-AD index) and brain age (SPARE-BA) atrophy.[Results] We identified four tau (I–IV) and three atrophy clusters. Tau clusters were associated with the apolipoprotein E genotype. Atrophy clusters were associated with white matter hyperintensity volumes. Only the hippocampal sparing atrophy cluster showed a specific association with brain aging imaging index. Tau clusters presented stronger clinical associations than atrophy clusters. Tau and atrophy clusters were partially associated.[Conclusions] Each neuroimaging modality captured different aspects of brain aging, genetics, vascular changes, and neurodegeneration leading to individual multimodal phenotyping.Jon B. Toledo is supported by the Edmond J. Safra Fellowship in Movement Disorders. Michel J. Grothe is supported by the “Miguel Servet” program (CP19/00031) and a research grant (PI20/00613) of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). This study was supported in part by the National Institute of Health (NIH) grant P30AG066546 (South Texas Alzheimer's Disease Research Center) and grant numbers 5R01HL127659, 1U24AG074855 and the San Antonio Medical Foundation grant SAMF–1000003860. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).Peer reviewedAlzheimer’s AssociationJohn Wiley & SonsMichael J. Fox Foundation for Parkinson's ResearchInstituto de Salud Carlos IIIEuropean CommissionNational Institutes of Health (US)San Antonio Medical FoundationNational Institute on Aging (US)National Institute of Biomedical Imaging and Bioengineering (US)AbbVie PharmaceuticalsAlzheimer's AssociationAlzheimer Drug Discovery FoundationAraclon BiotechBioClinicaBiogenBristol-Myers SquibbCereSpirCogstateEisaiElan PharmaceuticalsEli Lilly and CompanyEuroImmun DiagnosticsHoffmann-La RocheGenentechFujirebio EuropeGE HealthcareIXICOJanssen Alzheimer ImmunotherapyJohnson and Johnson Pharmaceutical Research and DevelopmentLumosityLundbeckMerck & CoMeso Scale DiagnosticsNeuroRxNeurotrackNovartisPfizerPiramal ImagingServierTakeda Pharmaceutical CompanyTransition TherapeuticsCanadian Institutes of Health ResearchToledo, Jon B. [0000-0003-4366-9268]Habes, Mohamad [0000-0001-9447-5805]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232022info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/305454https://api.elsevier.com/content/abstract/scopus_id/85138700262reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1002/trc2.12305Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3054542026-05-22T06:33:51Z
score 15,812455

Registos relacionados